GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Unipharma Co Ltd (ROCO:6621) » Definitions » Debt-to-Equity

Unipharma Co (ROCO:6621) Debt-to-Equity : 0.05 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Unipharma Co Debt-to-Equity?

Unipharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$3.70 Mil. Unipharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$12.93 Mil. Unipharma Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was NT$306.34 Mil. Unipharma Co's debt to equity for the quarter that ended in Jun. 2024 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Unipharma Co's Debt-to-Equity or its related term are showing as below:

ROCO:6621' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.04   Max: 0.06
Current: 0.05

During the past 11 years, the highest Debt-to-Equity Ratio of Unipharma Co was 0.06. The lowest was 0.00. And the median was 0.04.

ROCO:6621's Debt-to-Equity is ranked better than
81.98% of 827 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs ROCO:6621: 0.05

Unipharma Co Debt-to-Equity Historical Data

The historical data trend for Unipharma Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unipharma Co Debt-to-Equity Chart

Unipharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.04 0.02 0.01 -

Unipharma Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.01 - 0.05

Competitive Comparison of Unipharma Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unipharma Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Unipharma Co's Debt-to-Equity falls into.



Unipharma Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Unipharma Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Unipharma Co's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Unipharma Co  (ROCO:6621) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Unipharma Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Unipharma Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Unipharma Co Business Description

Traded in Other Exchanges
N/A
Address
Jiu Zong Road, 3rd Floor, No. 17, Lane 171, Section 2, NeiHu District, Taipei, TWN, 11494
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.

Unipharma Co Headlines

No Headlines